New Taipei City, Taiwan, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that its subsidiary, Health Ever Bio-Tech Co., Ltd., has been honored with the ...

New Taipei City, Taiwan, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that its chairwoman and chief executive officer, Fu Feng Kuo, has been invited to ...

核心观点 - 公司完成前列腺癌预防药物MCS-8的II期临床试验患者招募 关键里程碑达成 涉及超过700名高风险受试者[1][3] 临床试验进展 - MCS-8为植物源研究性新药 目前尚未在任何地区获批商业使用[3] - 试验采用随机安慰剂对照设计 在台湾20家医院开展 超过130名泌尿科医生参与[2] - 治疗期结束后将进行试验数据分析 结果将按披露要求公布[3] 公司业务定位 - 总部位于台湾的科学驱动型生物技术公司 专注于开发差异化植物源新药[1][4] - 主要深耕泌尿系统疾病治疗领域 初期聚焦美国、欧盟及亚洲市场[1][4] - 具备完整药物开发能力 涵盖早期研发、临床试验、注册事务、生产及商业化全链条[4] 研发管线布局 - 公司自2002年成立以来 依托自主研发能力和专有平台开发生物药管线[4] - 核心临床阶段植物药候选药物包括BOTRESO®及MCS-8 另拥有临床前阶段候选药物[4]

New Taipei City, Taiwan, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced its participation in the 22 Urological Association of Asia Congress which was held in co ...

个股跌幅表现 - Mint股价下跌33.18%至5.660美元 成交额1760.69万美元 [1] - e家快服股价下跌21.15%至1.100美元 成交额51.47万美元 [1] - 健永生技股价下跌18.46%至40.410美元 成交额1375.47万美元 [1] - AirNet Technology股价下跌17.77%至2.800美元 成交额196.45万美元 [1] - 天演药业股价下跌16.59%至1.910美元 成交额33.98万美元 [1] 市场交易特征 - 跌幅最大个股Mint单日下跌2.810美元 [1] - 健永生技成交额最高达1375.47万美元 [1] - e家快服成交额最低为51.47万美元 [1] - 五只个股跌幅均超过16% 呈现普跌态势 [1]

My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Business Management from Universidad Andina Simon Bolivar, Quito, Ecuador, and the Ph.D. degree in computer applications from the University of Alicante, Spain.Disclosure: I collaborate professionally with Edgar Torres H, who is also an author on Seeking ...

The Company's Chairwoman, Fu-Feng Kuo, commented: "We believe that from the international resonance of BIO 2025 to the completion of our IPO and the listing of our shares on Nasdaq, Jyong Biotech is poised for global prominence. Anchored in clinical evidence, we are committed to meeting the urgent demand for safe medications in an aging society, setting a new standard for plant-based new drug innovation on a global scale." About Jyong Biotech Ltd. Headquartered in Taiwan, Jyong Biotech Ltd.is a science-driv ...